Zantac Heartburn Medication Contains Cancer Carcinogens
On September 30, 2019, the FDA announced that ranitidine (Zantac), a heartburn medication used by millions of Americans, may cause cancer. Zantac has been found to contain a carcinogenic chemical 26,000 times the FDA-approved limit. When one 150 mg tablet is ingested, it undergoes a chemical reaction in the stomach to create more than 3,100 times the FDA-approved limit of N-nitrosodimethylamine (NDMA), a chemical which the FDA, EPA and World Health Organization classify as a dangerous carcinogen.
A newly filed class-action lawsuit accuses Sanofi, the maker of Zantac, of intentionally concealing risks of taking the medication to avoid sales and profit losses. Zantac was first sold in starting in1983, and three years later it became the first drug to total $1 billion in annual sales. The Plaintiffs in the class-action lawsuit are from all over the United States, and many of them took Zantac daily for years.
On October 1, 2019, Walgreens and CVS Pharmacies suspended sales of Zantac and removed the product from their store shelves.
INSERRA l KELLEY l SEWELL wants you and yours to know that if you are taking Zantac, please consult with your physician to find out if you should immediately start taking an alternative medication.
If you or a loved one suffered from severe side effects or cancer from Zantac, please call the great mass tort Team at Inserra Kelley Sewell to see whether you might be entitled to compensation.